口服胰岛素诱导机体产生针对胰岛自身抗原的免疫耐受 ,是治疗 1型糖尿病的一条新途径。其机制可能为通过激活肠道相关淋巴组织 ,诱导选择性免疫反应 ,导致局部Th2型细胞激活 ,分泌Th2型细胞因子 ,进而抑制Th1型细胞因子的分泌 ,避免胰岛细胞的破坏。“旁路抑制”理论是选择胰岛素作为口服抗原的理论基础。佐剂的应用可明显降低糖尿病的发生率 ,减少胰岛素的用量。口服胰岛素诱导免疫耐受的人群试验正在进行中 Oral insulin induces the body to produce immune tolerance against islet autoantigens, a new approach for the treatment of type 1 diabetes. The mechanism may be through activation of intestinal-related lymphoid tissue, induced by selective immune response, leading to local Th2-type cell activation, secretion of Th2-type cytokines, thereby inhibiting the secretion of Th1-type cytokines, to avoid destruction of islet cells. The “bypass inhibition” theory is the theoretical basis for choosing insulin as an oral antigen. The application of adjuvant can significantly reduce the incidence of diabetes and reduce the amount of insulin. Oral insulin-induced immune tolerance trials in humans are underway